Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 27, 2017 - Issue 8
Submit an article Journal homepage
988
Views
10
CrossRef citations to date
0
Altmetric
Letter to the Editor

Highly selective A3 adenosine receptor agonists relieve chronic neuropathic pain

Daniela SalveminiDepartment of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, MO, USA
&
Kenneth A. JacobsonLaboratory of Bioorganic Chemistry, National Institute of Diabetes & Digestive & Kidney Diseases, National Institutes of Health, Bethesda, MD, USACorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0001-8104-1493
ORCID Icon
Page 967 | Published online: 20 Jun 2017

References

  • do Couto Maia R. Recent trends in neuropathic pain patents. Expert Opin Ther Pat. 2017;27: 539-546. DOI:10.1080/13543776.2017.1273349
  • Pina LTS, Gouveia DN, Costa JS, et al. New perspectives for chronic pain treatment: a patent review (2010-2016). Expert Opin Ther Pat. 2017;27:787–796. DOI:10.1080/13543776.2017.1297425
  • Janes K, Jacobson KA, Symons-Liguori AM, et al. Identification of A3 adenosine receptor agonists as novel non-narcotic analgesics. Br J Pharmacol. 2016;173:1253–1267.
  • Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain. 1988;33:87−107.
  • Chen Z, Janes K, Chen C, et al. Controlling murine and rat chronic pain through A3 adenosine receptor activation. Faseb J. 2012;26:1855–1865.
  • Little JW, Ford A, Symons-Liguori AM, et al. Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states. Brain. 2015;138:28–35.
  • Tosh DK, Crane S, Chen Z, et al. Rigidified A3 adenosine receptor agonists: 1-Deaza modification maintains high in vivo efficacy. ACS Med Chem Lett. 2015;6:804–808.
  • Luongo L, Petrelli R, Gatta L, et al. 5′-Chloro-5′-deoxy-ENBA, a potent and selective adenosine A1 receptor agonist, alleviates neuropathic pain in mice through functional glial and microglial changes without affecting motor and cardiovascular functions. Molecules. 2012;17:13712–13726.
  • Varani K, Vincenzi F, Targa M, et al. The stimulation of A3 adenosine receptors reduces bone-residing breast cancer in a rat preclinical model. Eur J Cancer. 2013;49:482–491.
  • Yan H, Zhang E, Feng C, et al. Role of A3 adenosine receptor in diabetic neuropathy. J Neurosci Res. 2016;94:936–946.
  • Jacobson KA, Tosh DK, Salvemini D A3 adenosine receptor agonists. WO080940. 2015.
  • Salvemini D Use of A3 adenosine receptor agonists for treatment of neuropathic pain. US9132131B2. 2015.
  • Salvemini D Inhibition of opioid antinociceptive tolerance and withdrawal in nociceptive pain therapy. US0087613. 2015.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.